---
title: Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
nct_id: NCT00440011
overall_status: COMPLETED
phase: PHASE4
sponsor: Allergan
study_type: INTERVENTIONAL
primary_condition: Glaucoma
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00440011.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00440011"
ct_last_update_post_date: 2019-04-25
last_seen_at: "2026-05-12T06:33:54.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

**NCT ID:** [NCT00440011](https://clinicaltrials.gov/study/NCT00440011)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 266
- **Lead Sponsor:** Allergan
- **Conditions:** Glaucoma, Ocular Hypertension
- **Start Date:** 2006-08
- **Completion Date:** 2007-10
- **CT.gov Last Update:** 2019-04-25

## Brief Summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Glaucoma or ocular hypertension in both eyes
* Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
* Best-corrected visual acuity of 20/100 or better in each eye
* Visual field within 6 months of study entry

Exclusion Criteria:

* Secondary glaucoma
* Active intraocular inflammation or macular edema
* Intraocular surgery or laser surgery within the past 3 months
```

## Arms

- **1** (EXPERIMENTAL)
- **2** (ACTIVE_COMPARATOR)

## Interventions

- **bimatoprost 0.03% eye drops** (DRUG) — bimatoprost 0.03% 1 drop nightly for 3 months
- **travoprost 0.004% eye drops** (DRUG) — travoprost 0.004% 1 drop nightly for 3 months

## Primary Outcomes

- **Intraocular Pressure (IOP)** _(time frame: Month 3)_ — Intraocular Pressure

## Secondary Outcomes

- **Tolerability - Conjunctival Hyperemia** _(time frame: Month 3)_

## Locations (1)

- San Diego, California, United States

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|san diego|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00440011.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00440011*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*